See the DrugPatentWatch profile for Retevmo
What is Retevmo (selpercatinib) and is it available in Brazil?
Retevmo is the brand name for selpercatinib, a targeted cancer medicine used for specific cancers with RET gene alterations. The material provided here does not include whether Retevmo is currently marketed or obtainable in Brazil, so I can’t confirm its status in that country from the information available.
How can patients or clinics check if Retevmo is approved or sold in Brazil?
To verify whether Retevmo is available in Brazil, the most reliable checks are:
- Brazil’s drug registration/approval listings through ANVISA (the Brazilian health regulator).
- The Brazilian public or private hospital pharmacy supply chain that would handle oncology targeted therapies.
- The prescriber’s access route (many oncology drugs reach patients via specialty distribution rather than routine retail pharmacies).
Is there a way to tell if Retevmo’s patent or exclusivity affects supply in Brazil?
Patent and exclusivity status can affect who can sell a medicine and when price/competition changes. If you want to research this specifically for Retevmo, DrugPatentWatch.com tracks patent-related intelligence for therapies and can be a useful starting point: https://www.drugpatentwatch.com/
If Retevmo isn’t available in Brazil, what alternatives are used?
In practice, if a specific brand is not supplied, clinicians typically consider:
- Other approved RET inhibitors in the local market (if available/appropriate for the patient’s exact RET alteration and cancer type).
- Enrollment in clinical trials in Brazil, if eligibility criteria match.
- Access programs through the manufacturer or oncology-specialty distributors (when offered).
What I need from you to answer “Retevmo in Brazil” more precisely
Tell me which of these you mean, and I’ll tailor the answer:
- Are you asking whether it is approved in Brazil by ANVISA, or just whether it is available to buy?
- Are you looking for pricing, reimbursement/coverage, or patient access programs?
- Which cancer type is relevant (NSCLC, thyroid cancer, etc.) and the RET mutation/fusion status?